Use of new, once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis. Is there anything new under the sun?

Lakatos, Péter László (2009) Use of new, once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis. Is there anything new under the sun? WORLD JOURNAL OF GASTROENTEROLOGY, 15 (15). pp. 1799-1804. ISSN 1007-9327

Preview

Text 1182080.pdf Download (649kB) | Preview

Abstract

5-aminosalicylate (5-ASA) agents remain the mainstay treatment in ulcerative colitis (UC). A number of oral 5-ASA agents are commercially available, including azobond pro-drugs, as well as delayed- and controlled-release forms of mesalazine. However, poor adherence due to frequent daily dosing and a large number of tablets has been shown to be an important barrier to successful management of patients with UC. Recently, new, once-daily formulations of mesalazine, including the unique multi-matrix delivery system and mesalazine granules, were proven to be efficacious in inducing and maintaining remission in mild-to-moderate UC, with a good safety profile comparable to that of other oral mesalazine formulations. In addition, they offer the advantage of a low pill burden and might contribute to increased long-term compliance and treatment success in clinical practice. This editorial summarizes the available literature or, the short- and medium-term efficacy and safety of the new once-daily mesalazine formulations.

Actions (login required)

Edit Item